Medical Condition News

RSS

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Surgeons now use minimally invasive robotic surgical system for Whipple procedure

The Whipple procedure, used to remove tumors from pancreatic cancer patients, is one of surgery's most extensive and challenging operations.

11 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

St. Joseph's Hospital opens new $20 million Heart Institute

St. Joseph's Hospital entered the next era of cardiac care by opening a new $20 million Heart Institute on Feb. 10, 2014. St. Joseph's Hospital Heart Institute is one of the most advanced and comprehensive centers for cardiovascular medicine in Florida, performing more than 50,000 adult cardiac catheterizations. It is also has the only pediatric catheterization program in Hillsborough County.

11 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.

11 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Eternity Healthcare Inc., a medical device and diagnostic company specializing in diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood. The technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

From Medtronic 11 Feb 2014

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Cardiome Pharma Corp. today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS (vernakalant IV) to customers in the Swedish market.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Concussions account for 5.8% to 8.6% of injuries in soccer games

Soccer is the most-popular and fastest-growing sport in the world and, like many contact sports, players are at risk of suffering concussions from collisions on the field.

11 Feb 2014

Study: Urgency incontinence is the most troubling urinary symptom in men and women

Urgency incontinence is considered the most troubling urinary symptom in both men and women, according to a recent study published in the leading urology journal, European Urology.

11 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Researchers share findings on relations between gut flora and obesity

Cutting-edge European research presented at the 2014 AAAS meeting in Chicago. Three leading European researchers on the gut microbiome will be present at the 2014 AAAS meeting, on Saturday 15 February, to share their recent findings on the relations between gut flora and obesity, diabetes, and cardio-metabolic diseases in general.

11 Feb 2014

Body regulates hormone crucial for motivation and stress response, reveals research

New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.

11 Feb 2014

Researchers evaluate trends in cause-specific long-term mortality post PCI

More people who have known coronary heart disease die from other causes — such as cancer, and lung and neurological diseases — than heart disease, compared with 20 years ago, according to a Mayo Clinic study published online today in Circulation, an American Heart Association journal.

11 Feb 2014

Researchers examine link between alcohol consumption and breast cancer development

New research looking at the biological process involved in breast cancer development has strengthened the argument for a potential link between alcohol consumption and the disease.

From The University of Manchester 11 Feb 2014

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

EKF, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan DNA-enrichment tech.

From EKF Diagnostics 11 Feb 2014

New receptors act as biological postal code for treating cancer

Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells.

11 Feb 2014

Medical Condition News

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Surgeons now use minimally invasive robotic surgical system for Whipple procedure

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

St. Joseph's Hospital opens new $20 million Heart Institute

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Omeros announces additional positive data from OMS824 Phase 1 program

Concussions account for 5.8% to 8.6% of injuries in soccer games

Study: Urgency incontinence is the most troubling urinary symptom in men and women

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Researchers share findings on relations between gut flora and obesity

Body regulates hormone crucial for motivation and stress response, reveals research

Researchers evaluate trends in cause-specific long-term mortality post PCI

Researchers examine link between alcohol consumption and breast cancer development

EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

New receptors act as biological postal code for treating cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News